Japan PCSK9 Rivalry Builds As Praluent Edges Closer To Market
This article was originally published in PharmAsia News
Sanofi's Praluent looks set to become the second PCSK9 inhibitor available in Japan following a new recommendation for approval, but can it hold its own against launched rival Repatha? Meanwhile, AstraZeneca’s Brilinta is facing a delay.
You may also be interested in...
While Sanofi’s Japanese pharma business is feeling the impact of generic competition to its former blockbuster top product, it is aiming to move back into growth through a string of planned launches over the next few years.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.